



Published in final edited form as:

Int J Clin Rheumatol. 2011 ; 6(6): 617–623. doi:10.2217/IJR.11.6.

Depression in patients with rheumatoid arthritis: description, causes and mechanisms

Mary Margaretten^{*}, Laura Julian, Patricia Katz, and Edward Yelin

Department of Medicine, University of California, San Francisco, CA, USA

Abstract

Two sets of contributory factors to depression among patients with rheumatoid arthritis (RA) are generally examined – the social context of the individual and the biologic disease state of that person's RA. This article will review the evidence for both. RA affects patients both physically and psychologically. Comorbid depression is common with RA and leads to worse health outcomes. Low socioeconomic status, gender, age, race/ethnicity, functional limitation, pain and poor clinical status have all been linked to depression among persons with RA. Systemic inflammation may also be associated with, cause, or contribute to depression in RA. Understanding the socioeconomic factors, individual patient characteristics and biologic causes of depression in RA can lead to a more comprehensive paradigm for targeting interventions to eliminate depression in RA.

Keywords

depression; disability; pain; rheumatoid arthritis; socioeconomic status; systemic inflammation

Health effects of depression in rheumatoid arthritis

Chronic medical conditions are associated with an increased risk of depression and suicide [1]. Rheumatoid arthritis (RA), a chronic illness that affects 1.3 million adults in the USA [2], is a systemic inflammatory disease that affects people both physically and psychologically. Major depressive disorder is common in patients with RA, with a prevalence of 13–42% [3–9], at least double to four-times that in the general population. The wide range in the prevalence of depression in clinical studies of RA is likely due to the different methods used for measuring depressive symptoms. In patients with RA, poor clinical characteristics and function are associated with subsequent depressive symptoms [10].

Depression affects patients with RA beyond the burden of mental illness itself. Patients with RA and comorbid depression have worse health outcomes. Depression, a treatable condition, increases the risk of mortality in RA [11]. Specifically, depression in patients with RA is an

© 2011 Future Medicine Ltd

^{*}Author for correspondence: mary.margaretten@ucsf.edu.

Disclosure

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the NIH.

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

independent risk factor for cardiovascular disease [12] and myocardial infarction [13], suicidal ideation [14,15] and death [11,16–18] even after controlling for RA disease duration, disease activity, disability and pain. Also, patients with RA and associated depression have increased health service utilization [19] and are less likely to be adherent with their medications [20,21]. In addition to these negative health consequences, depression may contribute to unemployment, loss of work productivity and increased healthcare costs in persons with arthritis [22,23].

Comorbid depression in RA is especially troublesome because it often goes unrecognized and/or untreated [24,25]. Depression or depressive symptoms can be easily measured in RA using a variety of measures, from screening tools, such as the Center for Epidemiologic Studies Depression Scale, to diagnostic screening interviews [26], but rheumatologists rarely communicate about depression with their RA patients who have moderately severe-to-severe depressive symptoms [27]. The implication is that the burden of disease due to depression remains largely intact and is not adequately addressed by current health regimens. Addressing both the physical and psychological factors of RA during clinic visits is important because, as noted above, depression can impact mortality, health service utilization, and adherence to medications and self-care regimens. Regardless of whether rheumatologists refer RA patients to mental health professionals, communicate with the patient's primary care physician about the patient's depression or treat the depression themselves, it is important that rheumatologists are aware of the health impact of depression in RA.

As with most complex biologic systems, the relationship between depression and RA is multifactorial: in some cases it is likely that depression is mediated by the socioeconomic results of RA. In other cases, depression may be due to disability from RA, and/or the systemic inflammation from the proinflammatory cytokine milieu of RA. Regardless of the initiating factors, the contributory effect of the socioeconomic, functional and biologic consequences of RA can perpetuate depressive symptoms. Understanding the mechanistic components of depression in RA is critical for effective treatment (Box 1).

Socioeconomic factors related to depression in patients with RA

The terms 'socioeconomic status', 'social class' and 'socioeconomic position' (collectively known as SES) are broadly employed in health research, signaling the importance of socioeconomic factors for health outcomes. Low SES is generally associated with high psychiatric morbidity, depression [28] and mortality [29]. Poorer coping styles, ongoing life events, stress exposure and weaker social support are some examples of depression risk factors that are more prevalent in lower SES groups [30]. Regarding the direction of the association for SES and depression, results more consistently support the idea that causation (low SES increases risk of depression) outweighs selection (depression hinders social mobility), although both directions may operate simultaneously [28].

There is a substantial body of research linking SES, depression and RA [31,32]. However, despite expert consensus that SES is multifactorial, most health studies of SES in patients with depression and/or RA use a single socioeconomic variable measured at a single period and level [33]. Occupation is frequently used as a measure of SES in Europe [29,34,35] and education or income is more commonly used in the USA [36–38]. Yet, focusing on only one of these measures does not provide a complete picture. Standard occupational categories in the USA are inadequate measures of SES because categories include workers with diverse skills, earnings and/or prestige [39]. Education and income are not transposable and income can differ at similar education levels based on sex, age and racial/ethnic groups [33]. To illustrate this point, a recent US national survey found that multiple measures of SES,

including both low educational attainment and low income are independently associated with poor mental health and arthritis [40].

With notable exceptions [32,40–43], few studies of SES and depression in patients with RA have measured multiple indicators of SES. Future studies need more complete and better markers of SES. The importance of race/ethnicity in regard to SES is reflected in bias, culture, access to care, environmental and genetic factors, and should be included as a marker of SES [44]. For instance, arthritis affects some racial/ethnic populations disproportionately [45], and in fact, race/ethnicity has been shown to directly influence differences in depression scores in patients with RA [46]; yet few studies of depression in patients with RA include race/ethnicity as a covariate. When evaluating SES in the context of depression in patients with RA, future studies should acknowledge that socioeconomic factors interact with other social characteristics, such as race/ethnicity, to produce different health effects across groups. Not assessing SES differences that occur by income, education, race/ethnicity and geographic location ignores health disparities [47].

Another frequent omission in evaluating SES in patients with RA is neighborhood socioeconomic conditions. Despite increasing recognition that both individual and neighborhood level SES can influence health, few studies of depression in patients with RA measure neighborhood features. One prominent exception is a study by Harrison *et al.* that found significant relationships between area of residence and measures of health in patients with RA. Results suggested that patients from more socially deprived areas are more likely to experience more depression and poorer emotional health [41]. We recommend that future studies include measures of individual income, education, occupation, race/ethnicity and neighborhood socioeconomic conditions. If these variables are not included, then the missing measures should be identified as absent when stating conclusions.

Box 1. Characteristics associated with depression in rheumatoid arthritis

- Socioeconomic factors
 - Income
 - Education
 - Employment
 - Race/ethnicity
 - Neighborhood conditions
- Patient factors
 - Gender
 - Age
 - Race/ethnicity
 - Comorbidities
 - Coping mechanisms/social support
- Rheumatoid arthritis disease factors
 - Inflammation
 - Disease activity
 - Pain

- Functional status/disability
- Clinical remission

Patient & RA disease factors related to depression

Female gender and younger age have well-known associations with depression and confound the SES-depression relationship in RA [4,5,36,48]. As women have a higher prevalence of RA and depression, ignoring gender will falsely increase the magnitude of other variables associated with depression. Conversely, overlooking age tends to suppress other covariate effects because age has a U-shaped relation with depression [49]. As mentioned above, race/ethnicity is an important factor to include in measures of SES but is also a patient characteristic independently associated with depression in RA. Specifically, Asians with RA report less depression [46] while Hispanics with RA, particularly those who are not fully acculturated to mainstream Anglo society, report more depression [50].

Comorbidities and pain are commonly associated with both RA and depression [51,52]. Not surprisingly, pain has been indicated as a mechanism along the causal pathway for depression in those with RA [53–56]. Furthermore, depression may confound self-reports of pain [57]. Alternatively, pain in a patient with RA and comorbid depression could be diagnostic overshadowing – a process where the physical symptoms of RA are misattributed to depression [58].

There is conflicting evidence as to whether or not RA disease activity measured by rheumatologist-documented swollen, tender joints affects depression. Some studies show a positive correlation between depression and RA disease activity scores [59–61] while others do not [32,46]. Regardless of acute disease activity measures, there is no doubt that limited function, as measured by the Health Assessment Questionnaire, is a strong predictor of depression in patients with RA [5,10,11,54,56,59,62,63]. Taking this one step further, loss of valued activities beyond functional decline has been shown to lead to depression [10,63]. This suggests that depression in RA may not be caused by the acute clinical manifestations of RA disease activity but instead caused by the long-term disability and joint damage associated with arthritis that results in the loss of valued activities.

With regard to RA disease treatment, it is not unexpected that patients who achieve clinical remission are less likely to remain depressed compared with those who do not achieve RA remission [59]. The converse is true as well – patients who exhibit persistent depressive symptoms have poorer response to treatment and smaller reductions in their DAS28 scores [64]. A common element in the proposed mechanisms linking patient and RA disease characteristics to depression is the ability to adapt to the burden of RA disease and its treatment [62]. Positive coping mechanisms, social support (i.e., being married) [3,19] and having a sense of control over one's RA are also associated with decreased depressive symptoms [31].

Inflammation & depression in patients with RA

More recent studies have shown that systemic inflammation, measured by acute-phase reactants and proinflammatory cytokines, are often associated with the development of depression [65–67], and it has been suggested that systemic inflammation may be associated with, cause, or contribute to depressive symptoms during disorders of chronic inflammation [68–70]. In patients with RA, there is conflicting evidence regarding the association of the acute-phase reactant, high-sensitivity C-reactive protein, with depression [54,71]. The

hypothesis that systemic inflammation contributes to the high prevalence of depressive symptoms in patients with RA is supported by the following observations.

First, inflammatory cytokines and acute-phase reactants are increased in depressive symptoms in patients without RA. Compared with nondepressed individuals, depressed patients have activated inflammatory pathways, including increased expression of chemokines, adhesion molecules and cytokines [72–74]. Patients with major depression have increased serum and/or plasma concentrations of C-reactive protein [75,76], IL-6 [77,78] and proinflammatory TNF- α [79–82]. Elevations of these cytokines and acute-phase reactants exist in both serum and cerebrospinal fluid in depressed patients [83–86]. Furthermore, experimental human studies have demonstrated development of depressive symptoms following infusions of cytokines such as IFN- α [87,88].

Second, elevated levels of cytokines such as IL-6 and TNF- α may predict nonresponse to treatment for depressive symptoms. Prior data show that depressed patients with increased inflammatory biomarkers may be less likely to respond to conventional antidepressant treatments [89]. Also, patients with a history of poor response to traditional antidepressants have increased plasma levels of IL-6, TNF- α and acute-phase reactants [90–92]. In addition, depressed patients with higher levels of TNF- α experience a decrease to normal control values after antidepressant treatment [81].

Third, there is evidence that anti-inflammatory therapies have clinical benefit in reducing depressive symptoms. Acetylsalicylic acid, which blocks COX-1, COX-2 and the production of prostaglandins, when combined with fluoxetine led to higher remission rates in an open-label study of depressed patients previously nonresponsive to fluoxetine alone [93]. Also, in a randomized trial, depressed patients who received the selective COX-2 inhibitor, celecoxib, in combination with reboxetine demonstrated fewer depressive symptoms compared with patients receiving reboxetine and placebo [94].

Fourth, it has been suggested that medications such as traditional disease modifying antirheumatic drugs and biologics influence the relationship between inflammation and depression in patients with RA. Randomized placebo-controlled trials have demonstrated that prednisone, disease modifying antirheumatic drugs and TNF- α antagonist medications have improved quality of life and functional outcomes in patients with RA, but few have specifically evaluated their effect on depressive symptoms. One study has shown that patients with persistent depressive symptoms tended to respond less well to anti-TNF, with smaller reductions in RA disease activity [64]. A randomized trial of etanercept for the treatment of another autoimmune disease, psoriasis, showed that participants receiving the TNF- α antagonist medication had significant improvement in depressive symptoms independent of improvement in disease activity [95].

The interactions between predictors of depression in patients with RA

None of the factors associated with depression in patients with RA exist in a vacuum. For example, a significant interaction exists between socioeconomic status and disability [43] for patients with RA and comorbid depression. The association of disability with depression was stronger for persons of lower SES compared with those with higher SES. The tacit assumption that disability and socioeconomic status have independent consequences on depression in patients with RA does not hold. One potential explanation is that at every level of functioning, persons from lower SES may not have the support or coping resources to perform as well as those from higher SES, leading to even higher rates of depression. RA affects people both physically and psychologically, and by focusing on the interactions between societal, individual, contextual and biologic causes of depression in RA, rheumatologists can consider a more comprehensive paradigm. This is true for other

autoimmune diseases as well, such as systemic lupus erythematosus, where low SES is associated with health disparities in patient traits, levels of systemic disease/inflammation and a high prevalence of depression all coexist [96–98].

Future perspective

With the current national goals of public health research, we should anticipate effective policy development and interventions for reducing health disparities associated with SES, depression and RA. In addition, the rapid advances in immunology may lead to more persuasive data that systemic inflammation contributes to depression in RA. The first step has been made of acknowledging the high prevalence of depression in RA and its serious negative health outcomes. Now, rheumatologists must consider depression as a consequence of both social context and biologic RA disease factors in order to assess which aspects contribute the most to depression in patients with RA. In the next 10 years, rheumatologists can substantially decrease depressive symptoms in their patients by addressing the root causes of depression: preventing pain and disability, decreasing systemic inflammation and designing and implementing evidence-based programs to mitigate the effects of depression in RA [99,100]. This entails moving beyond associations to establish causal relationships that in turn can lead to new and targeted therapies for depression in patients with RA.

Executive summary

- Rheumatoid arthritis (RA) affects people both physically and psychologically and comorbid depression is common with a prevalence of 13–42%.
- Patients with RA and depression have worse health outcomes, including poor medication adherence, increased health service utilization, pain, disability and death.
- Low socioeconomic status is associated with depression in RA and should include measures of income, education, occupation, race/ethnicity and neighborhood conditions.
- Patient characteristics associated with depression in RA are female gender, younger age, race/ethnicity, poor coping mechanisms and decreased social support.
- Rheumatoid arthritis disease factors associated with depression in RA include pain, functional status and clinical remission.
- Systemic inflammation may contribute to depression in patients with RA.

Acknowledgments

The project described was supported by Award Number KL2RR024130 from the National Center for Research Resources.

References

Papers of special note have been highlighted as:

- of interest
- of considerable interest

1. Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. *Arch. Intern. Med.* 2000; 160(10):1522–1526. [PubMed: 10826468]
2. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum.* 2008; 58(1):15–25. [PubMed: 18163481]
3. Abdel-Nasser AM, Abd El-Azim S, Taal E, El-Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. *Br. J. Rheumatol.* 1998; 37(4):391–397. [PubMed: 9619889]
4. Wright GE, Parker JC, Smarr KL, Johnson JC, Hewett JE, Walker SE. Age, depressive symptoms, and rheumatoid arthritis. *Arthritis Rheum.* 1998; 41(2):298–305. [PubMed: 9485088]
5. Pincus T, Griffith J, Pearce S, Isenberg D. Prevalence of self-reported depression in patients with rheumatoid arthritis. *Br. J. Rheumatol.* 1996; 35(9):879–883. [PubMed: 8810672]
6. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. *Psychosom. Med.* 2002; 64(1):52–60. [PubMed: 11818586]
7. Smedstad LM, Moum T, Vaglum P, Kvien TK. The impact of early rheumatoid arthritis on psychological distress. A comparison between 238 patients with RA and 116 matched controls. *Scand. J. Rheumatol.* 1996; 25(6):377–382. [PubMed: 8996472]
8. Lowe B, Willand L, Eich W, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. *Psychosom. Med.* 2004; 66(3):395–402. [PubMed: 15184703]
9. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. *Clin. Rheumatol.* 2007; 26(6):872–878. [PubMed: 16941197]
10. Katz PP, Yelin EH. Activity loss and the onset of depressive symptoms: do some activities matter more than others? *Arthritis Rheum.* 2001; 44(5):1194–1202. [PubMed: 11352254] . •• Identifies the association between loss of valued-life activities and depression in patients with rheumatoid arthritis.
11. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. *J. Rheumatol.* 2005; 32(6):1013–1019. [PubMed: 15940760]
12. Treharne GJ, Hale ED, Lyons AC, et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. *Rheumatology (Oxford).* 2005; 44(2):241–246. [PubMed: 15522922]
13. Scherrer JF, Virgo KS, Zeringue A, et al. Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis. *Gen. Hosp. Psychiatry.* 2009; 31(4):353–359. [PubMed: 19555796]
14. Timonen M, Viilo K, Hakko H, et al. Suicides in persons suffering from rheumatoid arthritis. *Rheumatology (Oxford).* 2003; 42(2):287–291. [PubMed: 12595624]
15. Tektonidou MG, Dasgupta A, Ward MM. Suicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007–2008 National Health and Nutrition Examination Survey. *Arthritis Care Res. (Hoboken).* 2011; 63(9):1322–1333. [PubMed: 21671421]
16. Treharne GJ, Lyons AC, Kitis GD. Suicidal ideation in patients with rheumatoid arthritis. Research may help identify patients at high risk. *BMJ.* 2000; 321(7271):1290. [PubMed: 11185760]
17. Fuller-Thomson E, Shaked Y. Factors associated with depression and suicidal ideation among individuals with arthritis or rheumatism: findings from a representative community survey. *Arthritis Rheum.* 2009; 61(7):944–950. [PubMed: 19565540]
18. Pincus T. Is mortality increased in patients with rheumatoid arthritis? *J. Musculoskeletal Med.* 1988; 5:27–46.
19. Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. *J. Rheumatol.* 1993; 20(5):790–796. [PubMed: 8336304]
20. McNamara D. Depression interferes with anti-TNF therapy. *Rheumatology News.* 2007; 6(6)

21. Matthey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. *J. Rheumatol.* 2010; 37(10):2021–2024. [PubMed: 20682674]
22. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. *Med. Care.* 2006; 44(4):304–310. [PubMed: 16565630]
23. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden cost of rheumatoid arthritis (RA), estimating cost of comorbid cardiovascular disease and depression among patients with RA. *J. Rheumatol.* 2009; 36(4):743–752. [PubMed: 19228658]
24. Nagyova I, Stewart RE, Macejova Z, van Dijk JP, van den Heuvel WJ. The impact of pain on psychological well-being in rheumatoid arthritis: the mediating effects of self-esteem and adjustment to disease. *Patient Educ. Couns.* 2005; 58(1):55–62. [PubMed: 15950837]
25. Newman S, Mulligan K. The psychology of rheumatic diseases. *Baillieres Best Pract. Res. Clin. Rheumatol.* 2000; 14(4):773–786. [PubMed: 11092801]
26. Martens MP, Parker JC, Smarr KL, Hewett JE, Slaughter JR, Walker SE. Assessment of depression in rheumatoid arthritis: a modified version of the center for epidemiologic studies depression scale. *Arthritis Rheum.* 2003; 49(4):549–555. [PubMed: 12910563]
27. Sleath B, Chewning B, de Vellis BM, et al. Communication about depression during rheumatoid arthritis patient visits. *Arthritis Rheum.* 2008; 59(2):186–191. [PubMed: 18240190] . •• Evidence showing that rheumatologists rarely communicate about depression with their rheumatoid arthritis patients even after their patients initiate the conversation.
28. Lorant V, Deliege D, Eaton W, Robert A, Philippot P, Anseau M. Socioeconomic inequalities in depression: a meta-analysis. *Am. J. Epidemiol.* 2003; 157(2):98–112. [PubMed: 12522017]
29. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. *JAMA.* 2010; 303(12):1159–1166. [PubMed: 20332401]
30. Turner RJ, Lloyd DA. The stress process and the social distribution of depression. *J. Health Soc. Behav.* 1999; 40(4):374–404. [PubMed: 10643162]
31. Fitzpatrick R, Newman S, Archer R, Shipley M. Social support, disability and depression: a longitudinal study of rheumatoid arthritis. *Soc. Sci. Med.* 1991; 33(5):605–611. [PubMed: 1835800]
32. Berkanovic E, Oster P, Wong WK, et al. The relationship between socioeconomic status and recently diagnosed rheumatoid arthritis. *Arthritis Care Res.* 1996; 9(6):257–262. [PubMed: 9136289]
33. Braveman PA, Cubbin C, Egerter S, et al. Socioeconomic status in health research: one size does not fit all. *JAMA.* 2005; 294(22):2879–2888. [PubMed: 16352796] . •• Seminal paper describing which factors should be included when evaluating socioeconomic status for clinical research.
34. Stansfeld SA, Head J, Marmot MG. Explaining social class differences in depression and well-being. *Soc. Psychiatry Psychiatr. Epidemiol.* 1998; 33(1):1–9. [PubMed: 9448438]
35. Mackenbach JP, Kunst AE, Cavelaars AE, Groenhouf F, Geurts JJ. Socioeconomic inequalities in morbidity and mortality in western Europe. The EU Working Group on Socioeconomic Inequalities in Health. *Lancet.* 1997; 349(9066):1655–1659. [PubMed: 9186383]
36. Mitchell JM, Burkhauser RV, Pincus T. The importance of age education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. *Arthritis Rheum.* 1988; 31(3):348–357. [PubMed: 3358799]
37. Criswell LA, Katz PP. Relationship of education level to treatment received for rheumatoid arthritis. *J. Rheumatol.* 1994; 21(11):2026–2033. [PubMed: 7869305]
38. Hawley DJ, Wolfe F. Anxiety and depression in patients with rheumatoid arthritis: a prospective study of 400 patients. *J. Rheumatol.* 1988; 15(6):932–941. [PubMed: 3418643]
39. Krieger N, Fee E. Social class: the missing link in U.S. health data. *Int. J. Health Serv.* 1994; 24(1): 25–44. [PubMed: 8150566]
40. Furner SE, Hootman JM, Helmick CG, Bolen J, Zack MM. Health-related quality of life of US adults with arthritis: analysis of data from the behavioral risk factor surveillance system, 2003, 2005, and 2007. *Arthritis Care Res. (Hoboken).* 2011; 63(6):788–799. [PubMed: 21538946]

41. Harrison MJ, Tricker KJ, Davies L, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, longstanding rheumatoid arthritis. *J. Rheumatol.* 2005; 32(12):2330–2336. [PubMed: 16331758]
42. Harrison MJ, Farragher TM, Clarke AM, Manning SC, Bunn DK, Symmons DP. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. *Arthritis Rheum.* 2009; 61(10):1297–1304. [PubMed: 19790115] . ▪ First study to examine neighborhood socioeconomic status and factors of health in patients with rheumatoid arthritis.
43. Margaretten M, Barton J, Julian L, et al. Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. *Arthritis Care Res. (Hoboken).* 2011; 63(2):240–246. [PubMed: 20824800]
44. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. *N. Engl. J. Med.* 2003; 348(12):1170–1175. [PubMed: 12646676]
45. Bolen J, Schieb L, Hootman JM, et al. Differences in the prevalence and severity of arthritis among racial/ethnic groups in the United States, National Health Interview Survey, 2002, 2003, and 2006. *Prev. Chronic Dis.* 2010; 7(3):A64. [PubMed: 20394703]
46. Margaretten M, Yelin E, Imboden J, et al. Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. *Arthritis Rheum.* 2009; 61(11):1586–1591. [PubMed: 19877099]
47. Adler NE, Rehkopf DH. U.S. disparities in health: descriptions, causes, and mechanisms. *Annu. Rev. Public Health.* 2008; 29:235–252. [PubMed: 18031225]
48. Fifield J, Reisine S, Sheehan TJ, McQuillan J. Gender, paid work, and symptoms of emotional distress in rheumatoid arthritis patients. *Arthritis Rheum.* 1996; 39(3):427–435. [PubMed: 8607891]
49. Newmann JP. Aging and depression. *Psychol. Aging.* 1989; 4(2):150–165. [PubMed: 2675927]
50. Escalante A, del Rincon I, Mulrow CD. Symptoms of depression and psychological distress among Hispanics with rheumatoid arthritis. *Arthritis Care Res.* 2000; 13(3):156–167. [PubMed: 14635289]
51. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. *Clin. J. Pain.* 1997; 13(2):116–137. [PubMed: 9186019]
52. Nakajima A, Kamitsuji S, Saito A, et al. Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. *Mod. Rheumatol.* 2006; 16(3):151–157. [PubMed: 16767553]
53. Frank RG, Beck NC, Parker JC, et al. Depression in rheumatoid arthritis. *J. Rheumatol.* 1988; 15(6):920–925. [PubMed: 3418641]
54. Kojima M, Kojima T, Suzuki S, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. *Arthritis Rheum.* 2009; 61(8):1018–1024. [PubMed: 19644894] . ▪ Investigates association between C-reactive protein and depression in patients with rheumatoid arthritis.
55. Wolfe F, Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. *Arthritis Rheum.* 2009; 61(5):667–673. [PubMed: 19404997]
56. Smedstad LM, Vaglum P, Moum T, Kvien TK. The relationship between psychological distress and traditional clinical variables: a 2 year prospective study of 216 patients with early rheumatoid arthritis. *Br. J. Rheumatol.* 1997; 36(12):1304–1311. [PubMed: 9448592]
57. Ward MM. Are patient self-report measures of arthritis activity confounded by mood? A longitudinal study of patients with rheumatoid arthritis. *J. Rheumatol.* 1994; 21(6):1046–1050. [PubMed: 7932413]
58. Jones S, Howard L, Thornicroft G. 'Diagnostic overshadowing': worse physical healthcare for people with mental illness. *Acta Psychiatr. Scand.* 2008; 118(3):169–171. [PubMed: 18699951]
59. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. *Rheumatology (Oxford).* 2011; 50(2):401–409. [PubMed: 21059675]

60. Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. *Ann. Rheum. Dis.* 2007; 66(9): 1195–1201. [PubMed: 17392351]
61. Tander B, Cengiz K, Alayli G, Ilhanli I, Canbaz S, Canturk F. A comparative evaluation of health related quality of life and depression in patients with fibromyalgia syndrome and rheumatoid arthritis. *Rheumatol. Int.* 2008; 28(9):859–865. [PubMed: 18317770]
62. Covic T, Adamson B, Spencer D, Howe G. A biopsychosocial model of pain and depression in rheumatoid arthritis: a 12-month longitudinal study. *Rheumatology (Oxford)*. 2003; 42(11):1287–1294. [PubMed: 12810932]
63. Katz PP, Yelin EH. The development of depressive symptoms among women with rheumatoid arthritis. The role of function. *Arthritis Rheum.* 1995; 38(1):49–56. [PubMed: 7818571]
64. Hider SL, Tanveer W, Brownfield A, Matthey DL, Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. *Rheumatology (Oxford)*. 2009; 48(9):1152–1154. [PubMed: 19608723]
65. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. *Brain Behav. Immun.* 2003; 17 Suppl. 1:S119–S124. [PubMed: 12615197]
66. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom. Med.* 2009; 71(2):171–186. [PubMed: 19188531]
67. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. *Brain Behav. Immun.* 2007; 21(4):374–383. [PubMed: 17360153]
68. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat. Rev. Neurosci.* 2008; 9(1):46–56. [PubMed: 18073775]
69. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol. Psychiatry.* 2009; 65(9):732–741. [PubMed: 19150053]
70. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. *Biol. Psychiatry.* 2005; 58(3):175–189. [PubMed: 16084838]
71. Low CA, Cunningham AL, Kao AH, Krishnaswami S, Kuller LH, Wasko MC. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. *Biol. Psychol.* 2009; 81(2):131–134. [PubMed: 19428978]
72. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. *Am. J. Psychiatry.* 2001; 158(8):1252–1257. [PubMed: 11481159]
73. Bouhuys AL, Flentge F, Oldehinkel AJ, van den Berg MD. Potential psychosocial mechanisms linking depression to immune function in elderly subjects. *Psychiatry Res.* 2004; 127(3):237–245. [PubMed: 15296823]
74. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM. Inflammatory proteins and depression in the elderly. *Epidemiology.* 2003; 14(1):103–107. [PubMed: 12500057]
75. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. *Psychosom. Med.* 2003; 65(3):347–356. [PubMed: 12764206]
76. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. *Arch. Intern. Med.* 2004; 164(9):1010–1014. [PubMed: 15136311]
77. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. *J. Clin. Endocrinol. Metab.* 2005; 90(5):2522–2530. [PubMed: 15705924]
78. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. *Ann. NY Acad. Sci.* 1995; 762:474–476. [PubMed: 7668562]
79. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. *Trends Neurosci.* 2002; 25(3):154–159. [PubMed: 11852148]

80. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. *Eur. Neuropsychopharmacol.* 2001; 11(3):203–208. [PubMed: 11418279]
81. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. *Psychopharmacology (Berl)*. 2003; 170(4):429–433. [PubMed: 12955291]
82. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. *J. Ect.* 2003; 19(4):183–188. [PubMed: 14657769]
83. Maes M. Major depression and activation of the inflammatory response system. *Adv. Exp. Med. Biol.* 1999; 461:25–46. [PubMed: 10442165]
84. Appels A, Bar FW, Bar J, Bruggeman C, de Baets M. Inflammation, depressive symptomatology, and coronary artery disease. *Psychosom. Med.* 2000; 62(5):601–605. [PubMed: 11020087]
85. Irwin M. Psychoneuroimmunology of depression: clinical implications. *Brain Behav. Immun.* 2002; 16(1):1–16. [PubMed: 11846437]
86. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends Immunol.* 2006; 27(1):24–31. [PubMed: 16316783]
87. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. *N. Engl. J. Med.* 2001; 344(13):961–966. [PubMed: 11274622]
88. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. *Biol. Psychiatry.* 2004; 56(11):819–824. [PubMed: 15576057]
89. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. *Neuropsychopharmacology.* 2000; 22(4):370–379. [PubMed: 10700656]
90. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine.* 1997; 9(11):853–858. [PubMed: 9367546]
91. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. *Neuropsychobiology.* 1997; 35(3):123–127. [PubMed: 9170116]
92. Eller T, Vasar V, Shlik J, Maron E. Proinflammatory cytokines and treatment response to escitalopram in major depressive disorder. *Prog. Neuropsychopharmacol. Biol. Psychiatry.* 2008; 32(2):445–450. [PubMed: 17976882]
93. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. *Int. Clin. Psychopharmacol.* 2006; 21(4):227–231. [PubMed: 16687994]
94. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Mol. Psychiatry.* 2006; 11(7):680–684. [PubMed: 16491133]
95. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. *Lancet.* 2006; 367(9504): 29–35. [PubMed: 16399150]
96. Fernandez M, Alarcon GS, Calvo-Alen J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. *Arthritis Rheum.* 2007; 57(4):576–584. [PubMed: 17471524]
97. Liang MH, Rogers M, Larson M, et al. The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Rheum.* 1984; 27(1):13–19. [PubMed: 6691857]
98. Ward MM, Lotstein DS, Bush TM, Lambert RE, van Vollenhoven R, Neuwelt CM. Psychosocial correlates of morbidity in women with systemic lupus erythematosus. *J. Rheumatol.* 1999; 26(10): 2153–2158. [PubMed: 10529132]
99. Nicassio PM. The problem of detecting and managing depression in the rheumatology clinic. *Arthritis Rheum.* 2008; 59(2):155–158. [PubMed: 18240189] . ▪ Discusses how to identify patients in clinical practice with depression and rheumatoid arthritis.

100. Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis – underscoring the problem. *Rheumatology (Oxford)*. 2006; 45(11):1325–1327. [PubMed: 16908510]